Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 316237


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 316237

License Grant
Under the terms of the Asset Purchase Agreement with Party A, the Danish Licensee became party to a royalty agreement with the Trust for worldwide net sales of Arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS). Pursuant to this Asset Agreement, Party A sold and transferred certain preclinical and clinical data, patents and other intellectual property rights, and other assets, including contractual rights and obligations relating to a portfolio of chemical compounds, including arimoclomol, to Licensee.
License Property
Arimoclomol is an orally- or naso/gastrically-administered small molecule that crosses the blood-brain barrier and is designed to selectively amplify the natural role of endogenous Heat Shock Proteins (HSPs), which protect against cellular toxicity caused by protein misfolding, aggregation and lysosomal dysfunction.

The Trust is the charitable remainder beneficiary that generates a potential income stream from donors, or other beneficiaries, to benefit the research of ALS.

Amyotrophic lateral sclerosis or ALS, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS is often called Lou Gehrig's disease.

Field of Use
The Field of Use is for the treatment or prevention of Amyotrophic Lateral Sclerosis (ALS).  ALS, commonly referred to as Lou Gehrig’s disease, is a rapidly progressing neurological disease with the onset of symptoms typically occurring between 40 to 70 years of age, with patient mortality occurring in most patients within three to five years of disease onset. ALS attacks neurons responsible for controlling voluntary muscles, resulting in muscle weakness in limbs, and impacts speaking, chewing, swallowing and breathing, leading to progressive disability and eventually death, typically from respiratory failure and aspiration pneumonia.

Licensee is biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases that includes Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.

IPSCIO Record ID: 26578

License Grant
This Agreement is by and between Licensor, Trustee of the ALS Charitable Remainder Trust, dated August 28, 2006 and Licensee Charitable Trust shall transfer shares of Tribune Co. Common Stock and Berkshire Hathaway Inc. Class A and Class B Common Stock having a combined value of twenty four million five hundred thousand dollars ($24,500,000) (the royalty Shares) to an account designated by Licensee. For purposes of this Agreement, the royalty Shares shall be valued at the closing trading price of the shares on the date hereof on the New York Stock Exchange.  In consideration for the transfer of the royalty Shares, Licensee shall pay to Licensor royalties based on worldwide Net Sales of Arimoclomol by Licensee and Licensee Affiliates (as hereinafter defined) for treatment of Amyotrophic lateral sclerosis (ALS).
License Property
Amyotrophic lateral sclerosis, or ALS, is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement. Amyotrophic lateral sclerosis is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is the most common of the five motor neuron diseases.

IPSCIO Record ID: 352696

License Grant
Licensor is willing to grant to Licensee, a non-exclusive research license to conduct certain research to identify and select Specified Vectors for specified indications and an option to obtain a non-exclusive license to research, develop, and commercialize Licensed Products for specified indications.

For the Research License Grant, including the Retained Rights, during the Research Term, Licensor grants to Licensee a non-exclusive, non-transferable, worldwide license under the Licensed Research Patents to make, have made, and use any and all AAV Materials in the Research Field, including, for the avoidance of doubt, the right to conduct research and pre-clinical development, solely for purposes of identifying and selecting Specified Vector(s) for use in the Commercial Field upon exercise of a Commercial Option.  For the avoidance of doubt, the foregoing license does not include the right to sell, offer for sale, or import any AAV Materials.

For the Commercial License Option. Licensor grants to Licensee the option, exercisable at Licensees sole discretion, to obtain a non-exclusive worldwide license with respect to each of the Disease Indications and a single Specified Vector for such Disease Indication.

For the License Grant Upon Exercise, if Licensee exercises the Commercial Option for a
particular Disease Indication, effective upon both Licensors receipt of the notice and in the case of a Secondary Disease Indication, the fee described for such Secondary Disease Indication, including the Retained Rights. Licensor grants, to Licensee non-exclusive, sublicensable, non-transferable, worldwide license under the applicable Licensed Commercial Patents to make. have made, use, import, sell, and offer for sale Licensed Products using the Specified Vector solely in the Commercial Field for such Disease Indication, including, for the avoidance of doubt, the right to conduct research and development.

License Property
Licensor has rights under certain patents pertaining to various recombinant adeno-associated virus vectors.

AAVrh10 means the recombinant adeno-associated virus serotype rh10 vector with the specified sequence set forth in GenBank {protein id AAO88201) and (b) any recombinant
adeno-associated virus derivatives of such serotype rh10 vector that arc covered by the claims of the Licensed Research Patents.

Disease lndications means one or more of the following indications Friedreichs Ataxia that is treated or prevented by administration of the applicable recombinant adeno-associated virus serotype vector directly to the central nervous system, brain and spinal cord, Friedreichs Ataxia CNS, Friedreichs Ataxia that is treated or prevented by administration of the applicable recombinant adeno-associated virus serotype vector by any route except administration directly to the central nervous system, brain and spinal cord, Friedrcichs Ataxia Systemic, Huntingtons Disease, and  Amyotrophic Lateral Sclerosis.

Licensed Product means any product using the applicable Specified Vector capsid protein that is made, made for, used, sold, offered for sale, or imported by Licensee, its Affiliates, and any of its or their Sublicensees, the manufacture, use, sale. offer for sale, or import of which product, in the absence of the license granted pursuant to this Agreement, would infringe or is covered by at least one Valid Claim of the Licensed Commercial Patents in the country of manufacture, use, sale, offer for sale, or import; or any service sold by Licensee.

Field of Use
The license agreement for use of Licensor’s proprietary NAV® vectors for the development and commercialization of gene therapies to treat Amyotrophic Lateral Sclerosis (ALS), Friedreich’s ataxia (FA) and Huntington’s disease (HD).

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive, fatal neurodegenerative disease that leads to muscle weakness, loss of mobility, impaired speech, and difficulty breathing and swallowing.

Friedreich's ataxia (FA) is the most common hereditary ataxia, with approximately 8,000 patients living with the disease in the United States and Europe.  FA patients have a genetic mutation in the FXN gene, which limits the production of the protein frataxin, causing a variety of debilitating symptoms and complications, loss of coordination and balance, muscle weakness, impaired vision, hearing and speech, scoliosis, diabetes, and cardiomyopathy.

Huntington’s disease (HD) is an inherited neurodegenerative disorder where symptoms typically become noticeable between 30 and 50 years of age.  HD is caused by a genetic mutation in the huntingtin gene, which leads to the production of a mutated huntingtin protein, resulting in symptoms such as chorea, rigidity, abnormal posturing, cognitive impairment and psychiatric symptoms, and difficulty with speech and swallowing.

IPSCIO Record ID: 266764

License Grant
Foundation hereby grants to Licensee and its Affiliates and Licensee hereby accepts an exclusive, fully sublicenseable license under the Licensed Patents to practice the inventions claimed therein and to research, develop, make, have made, use, sell, offer for sale, have sold, import and otherwise exploit Licensed Products in the Licensed Territory during the term of this Agreement.
License Property
Licensed Patents shall mean U.S. Patent No. 5,952,357.

The Product shall mean the product known as Fampridine-SR for all indications.

Field of Use
The patent field of use includes treating a human with a disease of the anterior horn cells, to increase motor strength.

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease, is a specific disease that causes the death of neurons controlling voluntary muscles.

IPSCIO Record ID: 295927

License Grant
Licensor granted Licensee worldwide exclusive licenses, with the right to grant sublicenses, to our patent rights and know-how with respect to such compounds and products. Licensee is responsible for pursuing worldwide clinical development of compounds from the research program and has the exclusive right to develop and commercialize compounds from the collaboration  to further develop and commercialize compounds identified under our Foundation sponsored research program with the Foundation and to research other small molecule compounds with potential for therapeutic use in patients with Foundation.
License Property
Licensor developed several high-throughput drug discovery technology platforms that enable us to identify small molecule modifiers of pre-mRNA splicing. These technologies rely on sensitive quantification of pre-mRNA isoforms directly in human cells or tissue samples. Using this technology, we have successfully identified orally bioavailable small molecules that correct splicing of SMN2 mRNA. One of these molecules, risdiplam, is a potential treatment for the genetic disorder SMA.
Field of Use
The small molecule compounds with the potential for therapeutic use in patients with Spinal Muscular Atrophy (SMA).

Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy?) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center (distal). The muscle weakness usually worsens with age.

IPSCIO Record ID: 324064

License Grant
Licensor granted a license to the Licensee, a related party, to use its patent rights in order to develop and commercialize a treatment for ALS.
License Property
The patents relate to ALS (amyotrophic lateral sclerosis), a progressive, paralytic disorder characterized by degeneration of motor neurons in the brain and spinal cord.
Field of Use
The field of use is for the treatment of amyotrophic lateral sclerosis (ALS).  

ALS is a progressive, paralytic disorder characterized by degeneration of motor neurons in the brain and spinal cord.  Neuroinflammation in ALS is characterized by infiltration of lymphocytes and macrophages into the central nervous system, activation of microglia and reactive astrocytes, as well as the involvement of complement. Reactive astrocytes and microglia as well as infiltrating lymphocytes, dendritic cells, monocytes, macrophages and immune complexes have been identified in cerebrospinal fluid and neural tissues in animal models of ALS and at autopsy in patients.

IPSCIO Record ID: 26724

License Grant
This License Agreement provides for worldwide distribution rights for so long as there are patent rights and the parties continue their corporate existence.
License Property
BOW 304 is a drug being developed for the treatment of Multiple Sclerosis and related neurological symptoms.  The product is to be developed through a joint development and marketing agreement with a British based research and development partnership.

Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.

Field of Use
The rights granted relate to neurological symptoms.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.